IRIS
OYEN, Willem Jozef Gerard
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 41.515
AS - Asia 21.379
EU - Europa 5.485
SA - Sud America 2.919
AF - Africa 1.244
OC - Oceania 60
Continente sconosciuto - Info sul continente non disponibili 19
Totale 72.621
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 40.907
SG - Singapore 15.462
BR - Brasile 2.461
CN - Cina 2.058
VN - Vietnam 1.968
FI - Finlandia 1.375
IE - Irlanda 1.067
NG - Nigeria 917
FR - Francia 645
DE - Germania 631
HK - Hong Kong 439
NL - Olanda 415
GB - Regno Unito 402
CA - Canada 369
IT - Italia 301
IN - India 262
TR - Turchia 179
BD - Bangladesh 176
AR - Argentina 163
IQ - Iraq 130
MX - Messico 126
RU - Federazione Russa 116
SE - Svezia 112
IL - Israele 106
ZA - Sudafrica 93
PK - Pakistan 89
PL - Polonia 67
ES - Italia 63
JP - Giappone 61
UA - Ucraina 58
VE - Venezuela 55
EC - Ecuador 53
CL - Cile 50
CO - Colombia 50
MA - Marocco 50
ID - Indonesia 47
AU - Australia 45
KE - Kenya 45
UZ - Uzbekistan 45
SA - Arabia Saudita 41
JO - Giordania 34
TN - Tunisia 31
EG - Egitto 30
IR - Iran 30
PH - Filippine 30
AE - Emirati Arabi Uniti 29
PY - Paraguay 29
DZ - Algeria 27
MY - Malesia 25
CZ - Repubblica Ceca 24
JM - Giamaica 24
NP - Nepal 23
RO - Romania 23
AT - Austria 22
AZ - Azerbaigian 22
BO - Bolivia 21
PE - Perù 20
OM - Oman 19
KZ - Kazakistan 17
MD - Moldavia 17
LB - Libano 16
CR - Costa Rica 15
UY - Uruguay 15
BE - Belgio 14
CH - Svizzera 14
DO - Repubblica Dominicana 14
GR - Grecia 14
LT - Lituania 14
SN - Senegal 14
A2 - ???statistics.table.value.countryCode.A2??? 13
NZ - Nuova Zelanda 13
PA - Panama 12
AL - Albania 11
ET - Etiopia 11
HN - Honduras 11
PS - Palestinian Territory 11
RS - Serbia 11
PT - Portogallo 10
DK - Danimarca 9
BH - Bahrain 7
NI - Nicaragua 7
QA - Qatar 7
SY - Repubblica araba siriana 7
BG - Bulgaria 6
BY - Bielorussia 6
GT - Guatemala 6
HU - Ungheria 6
KR - Corea 6
NO - Norvegia 6
BB - Barbados 5
CI - Costa d'Avorio 5
HR - Croazia 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
XK - ???statistics.table.value.countryCode.XK??? 5
AM - Armenia 4
GE - Georgia 4
KW - Kuwait 4
PR - Porto Rico 4
TW - Taiwan 4
Totale 72.552
Salva come PNG Salva come JPEG
Città #
Chandler 7.378
Singapore 7.290
Wilmington 6.854
San Mateo 2.586
The Dalles 2.292
Ashburn 1.727
Ann Arbor 1.402
Shanghai 1.381
Helsinki 1.373
Leawood 1.222
Lawrence 1.117
Princeton 1.117
San Jose 1.080
Dublin 1.062
Boardman 1.009
Benin City 911
Fairfield 684
New York 663
Woodbridge 647
Ho Chi Minh City 638
Dallas 625
Paris 576
Hanoi 532
Hong Kong 397
Amsterdam 394
Seattle 370
San Diego 317
Beijing 285
London 247
Toronto 219
São Paulo 213
Los Angeles 181
Santa Clara 159
Norwalk 128
Milan 110
Da Nang 108
Kocaeli 103
Haiphong 86
Rio de Janeiro 85
Falkenstein 80
Belo Horizonte 71
Phoenix 66
Brooklyn 59
Montreal 55
Warsaw 55
Orem 48
Baghdad 47
Chicago 47
Tokyo 47
Houston 45
Johannesburg 45
Dhaka 43
Brasília 42
Pune 41
Tashkent 41
Porto Alegre 39
Moscow 38
Reston 36
Stockholm 35
Nairobi 34
Hải Dương 33
Campinas 31
Chennai 31
Hillsboro 31
Buffalo 30
Monmouth Junction 30
Munich 30
Amman 29
Biên Hòa 29
Curitiba 29
Des Moines 29
Redmond 29
Mexico City 28
Boston 26
Frankfurt am Main 26
Istanbul 24
Charlotte 23
Manchester 23
Ribeirão Preto 22
Salvador 22
Lahore 21
Can Tho 20
Council Bluffs 20
Erbil 20
Fortaleza 20
New Delhi 20
Quito 20
San Francisco 20
Atlanta 19
Guarulhos 19
Asunción 18
Buenos Aires 18
Denver 18
Nha Trang 18
Phủ Lý 18
Baku 17
Goiânia 17
Las Vegas 17
Riyadh 17
Cape Town 16
Totale 49.510
Salva come PNG Salva come JPEG
Nome #
(18)FDG-PET for staging (non)seminomatous germ cell tumours [(N)SGCT] and for evaluation of postchemotherapy residual masses. 122
18-F fluorodeoxygenase (FDG) positron emission tomography (PET) scanning prior to radical lung radiotherapy. A retrospective audit of practice 118
2-(F-18)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: A prospective study 115
[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer 107
[18F]FDG PET/CT in Large Vessel Vasculitis: The Impact of Expertise and Confounders on Image Analysis 104
Procedure guidelines for PET/CT tumour imaging with Ga-68-DOTA-conjugated peptides: Ga-68-DOTA-TOC, Ga-68-DOTA-NOC, Ga-68-DOTA-TATE 104
7TH ANNUAL-MEETING OF THE INTERNATIONAL RESEARCH GROUP IN IMMUNOSCINTIGRAPHY AND IMMUNOTHERAPY 102
Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor 102
Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients 102
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 101
18F-FLT-PET for the evaluation of MEK inhibitor AZD6244 100
F-18-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation 100
F-18-FDG PET/CT for Detection of Metastatic Infection in Gram-Positive Bacteremia 97
The Role of FDG-PET in the Assessment of Thyroid Nodules with an Indeterminant or Suspicious Cytologic Diagnosis 97
Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-68-DOTA-conjugated somatostatin receptor targeting peptides and F-18-DOPA 95
F-18-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis 95
18F-FDG PET/CT in Detecting Metastatic Infection in Children 95
[F-18]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma 95
F-18-FDG PET/CT for the Detection of Septic Embolisms in Patients with Infectious Endocarditis 95
[F-18]-Fluorination of a Leukotriene B4 Receptor Antagonist via Hydrazone Formation and its Application in Infection Imaging 95
3 '-Deoxy-3 '-F-18-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients 95
Kidney protection during peptide receptor radionuclide therapy (PRRT) 94
F-18-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients 94
Effect of the positron range on the spatial resolution of a new generation pre-clinical PET using fluorine-18, gallium-68, zirconium-89 and iodine-124 94
A direct comparison of four different Ga-68-labeled RGD peptides for PET/CT imaging of angiogenesis 94
18F-FDG-PET reduces the number of direct laryngoscopies in patients with suspected recurrent laryngeal carcinoma after radiotherapy 94
Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss 93
Improved selection of patients for hepatic surgery of colorectal liver metastases with FDG-PET: A randomized study 93
[F-18]fluoro-2-deoxy-d-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic e-cadherin mutation carrier 93
Radiation Exposure (Un)Awareness amongst nuclear medicine patients - a systematic review 93
Background-subtracted optimal threshold segmentation algorithm for FDG-PET based GTV delineation: Theory and experimental validation 92
99mTc-interleukin-8 for imaging acute osteomyelitis 92
F-18-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality 92
PET-CT for response assessment and treatment adaptation in head and neck cancer 91
New targeted probes for radioimaging of angiogenesis 91
A 3-step pretargeting strategy to image infection 91
F-18-FDG PET AS A PREDICTOR OF PULMONARY FUNCTION IN SARCOIDOSIS 91
The role of megalin in the renal uptake of radiolabeled peptides 90
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems 90
FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma 90
F-18-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis 90
A bivalent leukotriene B-4 antagonist for scintigraphic Imaging of infectious foci 90
F-18-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors 89
Pretargeted immuno-PET imaging and radioimmunotherapy of prostate cancer with an anti-EGP1 x anti-HSG bispecific antibody 89
Radioimmunotherapy with I-131-cG250 monoclonal antibody in patients with metastasized RCC, a phase I/II study. 89
In-111-anti-F4/80 for in vivo tracking of tumor associated macrophages 89
Comparison of liver SUV using unenhanced CT versus contrast- enhanced CT for attenuation correction in 18 F-FDGPET/CT 88
F-18-FDG PET of thyroid nodules with inconclusive cytologic results - Reply 88
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer 88
SPECT/CT-based Dosimetry for a Multicentre Trial of Selumetinib Enhanced Radioiodine Treatment of Differentiated Thyroid Cancer: Preliminary Results 87
INTERIM ANALYSIS OF A PHASE I RADIOIMMUNOTHERAPY STUDY IN ADVANCED RENAL CELL CARCINOMA PATIENTS USING LUTETIUM-177 LABELED MONOCLONAL ANTIBODY CG250 87
Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo 87
Progress in nuclear medicine procedures in head and neck oncology 87
In-111-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib 87
FDG-PET and CT in the staging of melanoma patients with lymph node metastases; diagnostic performance and clinical consequences 87
Clinical application of FDG-PET/CT in metastatic infections 87
FDG-PET in diagnosing central venous catheter related infection in stem cell transplant recipients 87
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 87
SORAFENIB REDUCES UPTAKE OF 111-INDIUM LABELED BEVACIZUMAB IN CLEAR CELL RENAL CELL CARCINOMA 86
Ga-68-labelled exendin-3, a new agent for the detection of insulinomas with PET 86
Zirconium-89-girentuximab PET/CT imaging in renal cell carcinoma: first in man results 85
EANM Focus 1: one small step for two men, one giant leap for a specialty 85
PET and SPECT imaging of rheumatoid arthritis with radiolabeled anti-FAP antibody correlates with severity of arthritis 85
Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody 85
Validated image fusion of dedicated PET and CT for external beam radiation therapy in the head and neck area 85
Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma 84
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer 84
Megalin Plays an Important Role in the Renal Uptake of Various Radiolabeled Peptides: Studies in Megalin-Deficient Mice 84
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes 84
F-18-fluorodeoxyglucose positron emission tomography of colonic anastomosis: A possibility to detect anastomotic leakage? A pilot study 84
IMPROVED SELECTION OF PATIENTS FOR HEPATIC SURGERY OF COLORECTAL LIVER METASTASES WITH FDG-PET: RESULTS OF THE RANDOMIZED DUTCH POLEM STUDY 83
Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer 83
Molecular imaging of hypoxia 83
Albumin derived peptides efficiently reduce renal uptake of radiolabeled peptides 83
Evaluation of the advanced ReSPECT image reconstruction software in a phantom model and in parathyroid scanning 83
A PHASE IB CLINICAL STUDY WITH 18F-FDG-PET RESPONSE EVALUATION OF THE COMBINATION OF TEMSIROLIMUS (T) AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN BREAST, ENDOMETRIAL AND OVARIAN CANCER 83
F-18-FDG PET in detecting metastatic infectious disease 83
Tumor segmentation and quantitative assessment of glucose metabolism for different histological types of NSCLC using dynamic F-18-FDG PET 83
Pulmonary sclerosing hemangioma detected by fluorodeoxyglucose positron emission tomography in familial adenomatous polyposis: Report of a case 82
Dynamic FDG PET in liver metastases of colorectal cancer: repeatability of dynamic and static FDG PET parameters. 82
Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic F-18 Fluorodeoxyglucose PET 82
Radiopharmaceuticals to image infection and inflammation 82
Imaging of cellular therapies 82
WHICH FACTORS PREDICT THE RESULTS OF PITUITARY SURGERY IN ACROMEGALY 82
A modelling approach to estimate the FDG arterial plasma time activity curve in Patlak-based therapy response analysis 81
Evaluation of a Ga-68-labelled Minigastrin for PET Imaging of CCK2/gastrin Receptor-Positive Tumours 81
SPECIFIC ANTIBODY UPTAKE IN TUBERCULOSIS 81
Radioimmunotheapy with [I-131]cG250 in patients with metastasized renal cell cancer: Dosimetric analysis and immunologic response 81
STERICALLY STABILIZED LIPOSOMES LABELED WITH IN-111 TO IMAGE FOCAL INFECTION 81
Radiolabeled IL-1ra for detection of synovitis in patients with RA. Preliminary results. 81
Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy 81
Y-86 and In-111 labeled alpha(V beta 3) binding peptides: A comparative dosimetric study in dogs. 81
F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection 81
In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging 80
Quantitative Assessment of Heterogeneity in Tumor Metabolism Using FDG-PET 80
Scintigraphic Techniques for Early Detection of Cancer Treatment-Induced Cardiotoxicity 80
Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring 80
PET/CT imaging of angiogenesis in head and neck squamous cell carcinoma patients 80
CAN FOG-PET PREDICT RADIATION TREATMENT OUTCOME IN HEAD AND NECK CANCER? 80
Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer 80
Totale 8.933
Salva come PNG Salva come JPEG
Categoria #
all - tutte 547.165
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 547.165
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.197 0 0 0 0 0 0 0 0 0 0 0 1.197
2021/20224.627 79 16 98 1.389 3 6 125 846 434 329 1.015 287
2022/202317.903 2.481 628 1.666 1.827 1.928 1.633 9 1.746 3.329 1.396 999 261
2023/20246.755 651 912 1.757 185 208 613 138 381 91 69 490 1.260
2024/20259.716 186 155 58 29 29 1.005 486 1.576 1.297 2.812 936 1.147
2025/202621.669 3.861 1.005 381 1.706 576 757 9.033 1.435 1.268 975 229 443
Totale 72.845